<SEC-DOCUMENT>0001140361-22-023541.txt : 20220621
<SEC-HEADER>0001140361-22-023541.hdr.sgml : 20220621
<ACCEPTANCE-DATETIME>20220621060349
ACCESSION NUMBER:		0001140361-22-023541
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220621
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220621
DATE AS OF CHANGE:		20220621

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IONIS PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000874015
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				330336973
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19125
		FILM NUMBER:		221025851

	BUSINESS ADDRESS:	
		STREET 1:		2855 GAZELLE COURT
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92010
		BUSINESS PHONE:		7609319200

	MAIL ADDRESS:	
		STREET 1:		2855 GAZELLE COURT
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ISIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>brhc10038943_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ions="http://ionispharma.com/20220621" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using EDGARfilings PROfile 8.4.0.0
         Copyright 1995 - 2022 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_e9822458f6be4a0ca73d1ba55de017e5" contextRef="c20220621to20220621" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_632c2555cdb24863ac172773537e9770" contextRef="c20220621to20220621">0000874015</ix:nonNumeric><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_070f4bd40b524b6bbdf98f167951ac00" contextRef="c20220621to20220621">NASDAQ</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="ions-20220621.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20220621to20220621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-21</xbrli:startDate><xbrli:endDate>2022-06-21</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

  <div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">Washington, D.C.&#160; 20549</div>

    <div>&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_70169c4ee13340078b2a24b67beab185" contextRef="c20220621to20220621">8-K</ix:nonNumeric></div>

    <div>&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT<span style="font-size: 10pt; font-family: 'Times New Roman';"><br />
      </span>PURSUANT TO SECTION&#160;13 OR 15(d) OF THE<span style="font-size: 10pt; font-family: 'Times New Roman';"><br />
      </span>SECURITIES EXCHANGE ACT OF 1934</div>

    <div>&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Date of report (Date of earliest event reported):&#160; <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_de7903e0daff4bdaa7ef1b4d693fad76" contextRef="c20220621to20220621" format="ixt:datemonthdayyearen">June 21, 2022</ix:nonNumeric></div>

    <div>&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_a1e076bfd38142858ffb1d4d55826d36" contextRef="c20220621to20220621">IONIS PHARMACEUTICALS, INC.</ix:nonNumeric><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Exact Name of Registrant as Specified in Charter)</div>

    <div>&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_d5a07f4426ad4ff69cf9f865a4c5b2bc" contextRef="c20220621to20220621" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(State or Other Jurisdiction of Incorporation)</div>

    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_693860c3e48c421cb534e005da55312a" contextRef="c20220621to20220621">000-19125</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_415061b3f76a4aa587735ca0cc1518b4" contextRef="c20220621to20220621">33-0336973</ix:nonNumeric><br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Commission File No.)</div>
          </td>

    <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(IRS Employer Identification No.)</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_9fdf2bbe0f3e416a8090a1cb73260eca" contextRef="c20220621to20220621">2855 Gazelle Court</ix:nonNumeric><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_96f7707543af4848adf2c92acd062e59" contextRef="c20220621to20220621">Carlsbad</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_2ff847f83ef741fe8c7e3f448aaf533d" contextRef="c20220621to20220621">CA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_76159b2900394dd7bc590ed092694cc8" contextRef="c20220621to20220621">92010</ix:nonNumeric></div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Address of Principal Executive Offices and Zip Code)</div>

    <div>&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Registrant&#8217;s telephone number, including area code: <span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_250ab0c77d6749b1bfc266f8adaf982b" contextRef="c20220621to20220621">760</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_cf983183a92b45e897fe09c2b593cdc5" contextRef="c20220621to20220621">931-9200</ix:nonNumeric></span></div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> <br />
      </span></div>

    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
      provisions:</div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_8af04d9cb2314a568e83a4038cdd53b3" contextRef="c20220621to20220621" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </td>

    <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
          </td>

  </tr>


</table>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_5be693247a234f5f9294838555aefc4a" contextRef="c20220621to20220621" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </td>

    <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
          </td>

  </tr>


</table>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_6dcc9a5576d0497183510cd074492692" contextRef="c20220621to20220621" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </td>

    <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
          </td>

  </tr>


</table>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_becaa2f074244991aff4b989cebaf6a2" contextRef="c20220621to20220621" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </td>

    <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 31.1%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Title of each class</div>
          </td>

    <td style="width: 4.7%; vertical-align: top;">&#160;</td>

    <td style="width: 17.22%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Trading symbol</div>
          </td>

    <td style="width: 4.57%; vertical-align: top;">&#160;</td>

    <td style="width: 42.41%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Name of each exchange on which registered</div>
          </td>

  </tr>

  <tr>

    <td style="width: 31.1%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_5d267e68428c41fc9ed90a716af9e301" contextRef="c20220621to20220621">Common Stock, $.001 Par Value</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 4.7%; vertical-align: top;">&#160;</td>

    <td style="width: 17.22%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<ix:nonNumeric name="dei:TradingSymbol" id="Fact_059342ef88e148f18803c6b45671fa17" contextRef="c20220621to20220621">IONS</ix:nonNumeric>&#8221;</div>
          </td>

    <td style="width: 4.57%; vertical-align: top;">&#160;</td>

    <td style="width: 42.41%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="-sec-ix-hidden:Fact_070f4bd40b524b6bbdf98f167951ac00">The Nasdaq Stock Market, LLC</span><br />
            </div>
          </td>

  </tr>


</table>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this
      chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).</div>

    <div style="text-align: right;"><span style="font-size: 10pt; font-family: 'Times New Roman';">Emerging growth company</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<a id="z_Hlk11148519"></a><span style="font-size: 10pt; font-family: 'Times New Roman';">&#160; &#160; &#160; <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_b64fd83df6ed4a369b556c983d35bd3b" contextRef="c20220621to20220621" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></span></div>

    <div>&#160;</div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
      revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#160; &#9744;</span></div>

    <div>&#160;</div>

    <div>
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /> </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">

      <div style="page-break-after:always;" class="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>


    </div>

    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
              <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Item 8.01</span></div>
            </td>

    <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Other Events.</span></div>
            </td>

  </tr>


</table>
    </div>

    <div>&#160;</div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">On June 21, 2022, Ionis Pharmaceuticals, Inc. issued a press release announcing that eplontersen met its co-primary and secondary endpoints in an interim
      analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).</div>

    <div>&#160;</div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">A copy of this press release is attached as Exhibit 99.1 to this Current Report and incorporated herein by reference.</div>

    <div>&#160;</div>

    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
              <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Item 9.01.</span></div>
            </td>

    <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Financial Statements and Exhibits.</span></div>
            </td>

  </tr>


</table>
    </div>

    <div>&#160;</div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">(d) Exhibits.</div>

    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 16%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="text-decoration: underline;">Exhibit No.</span></div>
          </td>

    <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>

    <td style="width: 82%; vertical-align: bottom;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="text-decoration: underline;">Description</span></div>
          </td>

  </tr>

  <tr>

    <td style="width: 16%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><a href="brhc10038943_ex99-1.htm">99.1</a></div>
          </td>

    <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 82%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Press Release dated June 21, 2022.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 16%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 82%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 16%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">104</div>
          </td>

    <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 82%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</div>
          </td>

  </tr>


</table>
    <div style="text-align: justify;"><br />
    </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">

      <div style="page-break-after:always;" class="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>


    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps; font-weight: bold;">SIGNATURE</div>

    <div>&#160;</div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
      its behalf by the undersigned, thereunto duly authorized.</div>

    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 55%; vertical-align: top;">&#160;</td>

    <td style="vertical-align: top;" colspan="3">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps; font-weight: bold;">Ionis Pharmaceuticals, Inc.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 55%; vertical-align: top;">&#160;</td>

    <td style="vertical-align: top;" colspan="3">&#160;</td>

  </tr>

  <tr>

    <td style="width: 55%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Dated:&#160; June 21, 2022</div>
          </td>

    <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">By:</div>
          </td>

    <td style="width: 35.89%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">/s/ Patrick R. O&#8217;Neil</div>
          </td>

    <td style="width: 5.86%; vertical-align: top; padding-bottom: 2px;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 55%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 35.89%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps; font-weight: bold;">Patrick R. O&#8217;Neil</div>
          </td>

    <td style="width: 5.86%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 55%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 35.89%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Executive Vice President, Chief Legal Officer and General Counsel</div>
          </td>

    <td style="width: 5.86%; vertical-align: top;">&#160;</td>

  </tr>


</table>
    <div><br />
    </div>

  </div>

  <div><br />
  </div>

  <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" />
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>brhc10038943_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, LLC
         Document created using EDGARfilings PROfile 8.4.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160; <img src="image00001.jpg"></div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Ionis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for <a name="z_Hlk99886847"></a>hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)</div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze11c4932d550410fb8cc915e7ecde6c4">

          <tr>
            <td style="width: 18pt;">
              <div><br>
              </div>
            </td>
            <td style="width: 18pt; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: italic;">&#8722;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Eplontersen showed statistically significant and clinically meaningful improvements in mNIS+7 and Norfolk QoL-DN</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4b8aad099cc147c2bdc16e434d811f03">

          <tr>
            <td style="width: 18pt;">&#160;</td>
            <td style="width: 18pt; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: italic;">&#8722;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Eplontersen demonstrated a favorable safety profile</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcdcfb10b11af49c29c8a9de862a232fd">

          <tr>
            <td style="width: 18pt;">&#160;</td>
            <td style="width: 18pt; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: italic;">&#8722;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Ionis and AstraZeneca expect to file a New Drug Application this year</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; color: #000000;">CARLSBAD, Calif., June 21, 2022</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;"> &#8211; </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Ionis Pharmaceuticals, Inc</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">. (Nasdaq: IONS) today announced positive topline results from a 35-week interim analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca&#8217;s eplontersen in patients with
        hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). Eplontersen demonstrated a statistically significant and clinically meaningful change from baseline for the co-primary endpoints of percent change in serum transthyretin (TTR)
        concentration and the modified Neuropathy Impairment Score +7 (mNIS+7), a measure of neuropathic disease progression, versus the historical placebo group. Eplontersen also met its key secondary endpoint of change from baseline in the Norfolk
        Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN), showing treatment with eplontersen significantly improved patient-reported quality of life versus the historical placebo group.</font></div>
    <div><br>
    </div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the study, eplontersen demonstrated a favorable safety and tolerability profile with no specific concerns. The study data are consistent
      with the clinical profile seen across Ionis&#8217; other LICA programs, further validating how advancements in the company&#8217;s <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">LI</font>gand-<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">C</font>onjugated <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">A</font>ntisense technology position Ionis
      to deliver potentially transformative treatments for a range of unmet medical needs.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">Based on these study results, the companies will seek regulatory
        approval for eplontersen for ATTRv-PN and plan to file a new drug application with the U.S. Food and Drug Administration this year</font>.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">&#8220;These encouraging data reinforce the safety profile of
        eplontersen and demonstrate clear evidence of its potential to provide much needed therapeutic benefit to patients living with hereditary transthyretin-mediated amyloid polyneuropathy,&#8221;</font> said Teresa Coelho, M.D., a neurologist and
      neurophysiologist at Hospital Santo Ant&#243;nio, Centro Hospitalar Universit&#225;rio do Porto, Portugal and an investigator for the NEURO-TTRansform study.</div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;We are pleased that the data in the NEURO-TTRansform study demonstrate eplontersen had a positive impact on disease progression, including improvement in
      neuropathy impairment and quality of life in a substantial number of patients. These highly statistically significant and clinically meaningful results put us on the cusp of providing a new <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">therapeutic option for polyneuropathy patients living with this debilitating and fatal disease,&#8221; said Eugene Schneider, M.D., Ionis&#8217; executive vice president and chief clinical development officer. &#8220;We are
        grateful to the patients, families and clinicians who are participating in NEURO-TTRansform. Without their commitment the eplontersen program would not have progressed as successfully as it has.&#8221;</font></div>
    <div><br>
    </div>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The data from the 35-week interim analysis will be presented at an upcoming medical meeting later this year.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As part of a global <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">development and commercialization</font> agreement between
      Ionis and AstraZeneca, eplontersen is being jointly developed and commercialized by both companies in the U.S. and will be developed and commercialized in the rest of the world by AstraZeneca (with the exception of Latin America).</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Eplontersen was <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">granted Orphan Drug Designation</font> in the U.S. It is also
      currently being evaluated in the Phase 3 CARDIO-TTRansform study for amyloid transthyretin cardiomyopathy (ATTR-CM), a systemic, progressive and fatal condition that leads to progressive heart failure and death within four years from diagnosis.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For more information on the NEURO-TTRansform study, please visit: <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">https://clinicaltrials.gov/ct2/show/NCT04136184</font>.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">About the NEURO-TTRansform Study</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">NEURO-TTRansform is a global, open-label, randomized study evaluating the efficacy and safety of eplontersen in patients with hereditary
      transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). The study has enrolled adult patients with stage 1 or stage 2 polyneuropathy and will compare efficacy of eplontersen to the historical placebo arm from the TEGSEDI<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (inotersen)
      NEURO-TTR registrational study that Ionis completed in 2017. The final primary endpoint analysis will be completed at week 66 and all patients will be followed until week 85 when they will have the option to transition into the open label extension
      study.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The co-primary efficacy endpoints at week 66 are:</div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z83133ee367ef445db7cbfc60a35c7edf">

          <tr>
            <td style="width: 18pt;">&#160;</td>
            <td style="width: 18pt; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percent change from baseline in serum TTR concentration</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf64d474554c149bf83b8d71de1e9ace1">

          <tr>
            <td style="width: 18pt;">&#160;</td>
            <td style="width: 18pt; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Change from baseline in the modified Neuropathy Impairment Score +7 (mNIS+7), a measure of neuropathic disease progression</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z114b3b7888d544bcb7ff7819ca3d084c">

          <tr>
            <td style="width: 18pt;">&#160;</td>
            <td style="width: 18pt; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Change from baseline in the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN)</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">About Eplontersen</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Eplontersen is an investigational antisense medicine that uses Ionis' advanced <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">LI</font>gand-<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">C</font>onjugated <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">A</font>ntisense,



      or LICA, technology designed to inhibit the production of the transthyretin (TTR) protein at its source. Eplontersen, which is planned to be delivered to patients via an autoinjector, is in development to treat all types of ATTR, a systemic,
      progressive and fatal disease.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">About Hereditary Transthyretin Amyloidosis (ATTRv)</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Hereditary transthyretin amyloidosis (ATTRv) is a severe, progressive, and life-threatening disease caused by the abnormal formation of the TTR protein and
      aggregation of TTR amyloid deposits in various tissues and organs throughout the body, including in peripheral nerves, the heart and intestinal tract. The progressive accumulation of TTR amyloid deposits in these organs often leads to intractable
      peripheral sensorimotor neuropathy, autonomic neuropathy, and/or cardiomyopathy, as well as other disease manifestations. Hereditary transthyretin amyloidosis causes significant morbidity and progressive decline in quality of life, severely impacting
      activities of daily living. The disease often progresses rapidly and can lead to premature death. The median survival is 4.7 years following diagnosis.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">About Ionis Pharmaceuticals, Inc.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense
      technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people
      depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">To learn more about Ionis, visit www.ionispharma.com and follow us on Twitter @ionispharma.</div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Ionis' Forward-looking Statements</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of Ionis' technologies,
      eplontersen and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements
      are subject to certain risks and uncertainties, including those related to the impact COVID-19 could have on our business, and including but not limited to, those related to our commercial products and the medicines in our pipeline, and particularly
      those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also
      involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently
      known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2021,
      and the most recent Form 10-Q quarterly filing, which are on file with the SEC. Copies of these and other documents are available from the Company.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers to Ionis Pharmaceuticals and its subsidiaries.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis Pharmaceuticals&#174; is a trademark of Ionis Pharmaceuticals, Inc.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis Investor Contact:</font> 760-603-2331</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis Media Contact:</font> 760-603-4679</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">+++</div>
    <div><br>
    </div>
    <div><br>
    </div>
  </div>
  <div>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ions-20220621.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<xs:schema targetNamespace="http://ionispharma.com/20220621" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:ions="http://ionispharma.com/20220621" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="ions-20220621_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ions-20220621_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://ionispharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2021" schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ions-20220621_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ions-20220621_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://ionispharma.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="ions-20220621.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://ionispharma.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !# ,L# 2(  A$! Q$!_\0
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B,R+EV^K')/XFBBC$-\U@X@JS]MR<SMVZ&U1117.?/'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140600543475424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 21, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 21,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IONIS PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-19125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0336973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2855 Gazelle Court<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carlsbad<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">931-9200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000874015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.001 Par Value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IONS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>brhc10038943_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ions-20220621.xsd" xlink:type="simple"/>
    <context id="c20220621to20220621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <startDate>2022-06-21</startDate>
            <endDate>2022-06-21</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20220621to20220621"
      id="Fact_e9822458f6be4a0ca73d1ba55de017e5">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20220621to20220621"
      id="Fact_632c2555cdb24863ac172773537e9770">0000874015</dei:EntityCentralIndexKey>
    <dei:SecurityExchangeName
      contextRef="c20220621to20220621"
      id="Fact_070f4bd40b524b6bbdf98f167951ac00">NASDAQ</dei:SecurityExchangeName>
    <dei:DocumentType
      contextRef="c20220621to20220621"
      id="Fact_70169c4ee13340078b2a24b67beab185">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20220621to20220621"
      id="Fact_de7903e0daff4bdaa7ef1b4d693fad76">2022-06-21</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20220621to20220621"
      id="Fact_a1e076bfd38142858ffb1d4d55826d36">IONIS PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20220621to20220621"
      id="Fact_d5a07f4426ad4ff69cf9f865a4c5b2bc">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20220621to20220621"
      id="Fact_693860c3e48c421cb534e005da55312a">000-19125</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20220621to20220621"
      id="Fact_415061b3f76a4aa587735ca0cc1518b4">33-0336973</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20220621to20220621"
      id="Fact_9fdf2bbe0f3e416a8090a1cb73260eca">2855 Gazelle Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20220621to20220621"
      id="Fact_96f7707543af4848adf2c92acd062e59">Carlsbad</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20220621to20220621"
      id="Fact_2ff847f83ef741fe8c7e3f448aaf533d">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20220621to20220621"
      id="Fact_76159b2900394dd7bc590ed092694cc8">92010</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20220621to20220621"
      id="Fact_250ab0c77d6749b1bfc266f8adaf982b">760</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20220621to20220621"
      id="Fact_cf983183a92b45e897fe09c2b593cdc5">931-9200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20220621to20220621"
      id="Fact_8af04d9cb2314a568e83a4038cdd53b3">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20220621to20220621"
      id="Fact_5be693247a234f5f9294838555aefc4a">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20220621to20220621"
      id="Fact_6dcc9a5576d0497183510cd074492692">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20220621to20220621"
      id="Fact_becaa2f074244991aff4b989cebaf6a2">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20220621to20220621"
      id="Fact_5d267e68428c41fc9ed90a716af9e301">Common Stock, $.001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20220621to20220621"
      id="Fact_059342ef88e148f18803c6b45671fa17">IONS</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20220621to20220621"
      id="Fact_b64fd83df6ed4a369b556c983d35bd3b">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M6&['EFN]/WCFZXTV#^S)**5K%C#].9TK:-FE2L03)C(N!5%L-;9\]^K:ZYB
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ML0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*T(_8&YB:N*1&+9
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M8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ >##55)E<G",0!@  G"<  !,
M             ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" !X,-54A>V8]5,$  "1$   &               @($-"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ >##55)^@&_"Q @  X@P   T
M             ( !E@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !X,-54
MEXJ[',     3 @  "P              @ %R#P  7W)E;',O+G)E;'-02P$"
M% ,4    " !X,-54'#AEZC\!   \ @  #P              @ %;$   >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ >##55"0>FZ*M    ^ $  !H
M         ( !QQ$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ >##55&60>9(9 0  SP,  !,              ( !K!(  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ]A,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="brhc10038943_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionispharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="brhc10038943_8k.htm">brhc10038943_8k.htm</File>
    <File>brhc10038943_ex99-1.htm</File>
    <File>ions-20220621.xsd</File>
    <File>ions-20220621_lab.xml</File>
    <File>ions-20220621_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "brhc10038943_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "brhc10038943_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ions-20220621_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ions-20220621_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ions-20220621.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 29,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ions",
   "nsuri": "http://ionispharma.com/20220621",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10038943_8k.htm",
      "contextRef": "c20220621to20220621",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "role": "http://ionispharma.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10038943_8k.htm",
      "contextRef": "c20220621to20220621",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001140361-22-023541-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-22-023541-xbrl.zip
M4$L#!!0    ( '@PU52\54YTF!$  %UD   3    8G)H8S$P,#,X.30S7SAK
M+FAT;>T\:7/;.);?MVK_ U:],^-4F1+O0[%=Y9:5Q-..[96<F:[YT@4"H(0)
M1:I!RI;ZU^\#2$K494L^XJ3'KE1$$@_ P\.[<1P-\U&,IJ,XR=K34,3\N#',
M\W&[U;J[NVO*+\U4#%JFKELMGF0Y3@AKE/ Q3[[> RZ+0YS-P:=K\'>6@C:"
M(&BITCEHQC<!0K-&Z]?/%WTR9".LK>(CNZ>+BG5LW%916('R++5-P[MOL 7$
MO,)T&ZPA"0/(LU]_[ETLP//-\ O05BYPDD6I&.&<IXELR=%T4S/=6B-:QLA2
M0_#>'*2W#[;C:Y91M3/)M '&XWD[$<Y"A4Q9 %5,0].-6A7*5NA8]0L%"GS>
M=BZV$C%H06D%2-))DHO9YE;+PJ66R40(EI!M-<K2I2H)YB3;#*^*EH S3C:#
M0L$R8#X66R"A9 F43<EP,Z@L66Y5Y.L3 A\W348NM'PV9MEF2D-Q2Q;+FKJL
MN>@$^&%1"5YX-AYB8)0F24<2W-3=.?!VR90JHG'RW_^%T-&08:J>X#GG><Q.
MCEK%;_GQ?S0-77#"DHQ1E*=M]+-(,16<#ACZP!,05XYCU$_CB636[!"=)Z19
MU%5_9RF9C%B2(R(8SJ&-2<:3 >J>?3SM11QX?I"AZ]X5/#+D-^VFWM1KM3OI
M>";X8)@CP-Q!&I)CK*.@:16B(Y9C)$>LL=\G_/:XT4F3'#K6;H"4#42*M^-&
MSJ9Y2U$ M:#N4:LD 3R&*9VA+)_%[+@1 ;P6X1&/9VWTMQL^8AFZ9'>HEXYP
M\K?W2)5G_ _61H8^SM\CV:Z&8SY(VBAF$7PA:9R*-OI)5W_O48C)UX$ R:!:
M512IO_=R,HXHOT6<'C?.^M<?N%0$GSBE+&E4&%&8[!@#-DF:,*ARQ*=MB3L3
MQ:."5H\ < E$%YR@!(]D5<;;IS +5,[$AQ@/&JJG#YCDO[' -TW;\2,W9#;6
M"?8L:H38<2C3#8\Y)>FF>8]%QPU2,5F>+MBMT%7'#=!O[3!-8X:3",=@*$[4
MSU%K":?M*'838+U9!W 4.#Y/*)O^PF8U5%W+)*;C.(2&INV[%B:&9WJ>Y5@>
M"SQ/?QC5$SD3OF>#2MT9JSX#W01X=4'B<3)@EU!20TKW],@.J:V'CFF';AC2
M*/ CP_4"Q\!$WP6IR]/^V>G_K2'46IY5P2(F523+3HZD;6UGRFI"LTC9VO90
MR!ZD%&I5V\UI1AMEL50IQXV,C\8QS,Q1:[F-HKMZ'^HU2R="O2E?HET.18U^
MXU!*.*9FLGKC5+Y'G FD^F,;+6#G_)?E^5FM?%)]6FY]#-1*:?4&'H3(ST#3
MG$BD--T%[5G56Y3-T:1;0*N2ZKWJI+5$AXIH<RJU:C+9 H%6>@644_&H]-10
M5 (=I@( 2WE&Q9L6IGF>CD"IC*<H2V-.41B#WIB7Y^FXC>S5PB&32E*IHNE"
M\93:Y1[%LZ2U0,GG3+Q'(RP&/-&D$FLC/,G3^2=1]**^2?6Y;8Q2E96#W-3!
M/KK5EKI5?;@KQQBF,07UU^]VOO3.;\Z[?71Z>8:ZOW8^G5Y^[*+.U>?/Y_W^
M^=5E';OG1<K<AM0_<38$DY:GR2$Z:W::?_W)<$'SF[IC!^OHG!3%+X>GOPW/
M#U>]SVBKQJML=F$YYYK.TPTW(#9CAF79NN[YH8FERO-"AD/#W\%2G/C:+^MJ
M[IN31=]&%N"H7O?R!O6ZUU>]FZ-LC),E?V"M_O8.016&0GD8A2=SU)*MG5Q_
MZ?6_G$(7-U<(./@&V+08K6&AJQXRG /Z#EU]0#>?NB_1?4UHY@)SVKF1/1J!
M9;_27#1.I*Y%:80$&Z<B1P?5.\.@;5F6(W8K?<BBF-%W[5*P'F3A:Z6WNX4V
MK_$R95Z@6TRG.)+6&V./149H4S>P(DP]=T^OAT+K(Z@PI'@V Z3!;3OY^R1A
MR#0.E<_Z^EQO;M6D#_AC/3;@F8Q)\Q7/!QM,]]PPHI9OV*8/+F04&M2FCN.;
M+K5VH.$)L/]Y'UU_.NU]/NUTO]R<=TXO^A!#7':::Q2K\?-+L^-!=PH#1'*\
MD@L7%$ X0_TQ(](?H8@GJ /A%W3R[GO28@_,)P1HJ0 Y4MF%?@Z<VRFB]4Y*
MET3$P;H7V;;I8FI'$:C^*(A\U\$V<4(S)/N)B$Q\2 <L9V.1WDJ<I(R<L1C?
M@;B\ZF0K&J!4H*M\""[JW\';SR@GDCQR]I?HM?-$YSB$B):P. ;%2\ G.&[(
M4 #>QYC2ZKUPZM3C8^/..T[SH7S1_S)W$L'+B_$X YCJ:8?XM#$W%HL 7#EV
MN3BIA>2H&B"M4"XQ<"0"MTSDG."XZ@G<U5K#I2WZ#H3@ X\9E(5,U./+P/)=
MG5C,]HEM&B1T+)OIND,A&K8,$^\67VI&8)CKX>62.:Z,\L)GKK[D],]'[!L\
M/2^C.**D:(WRMN'HKA%:D>=B&V/'EU$]P3HAAF/XH;T#Y2U+TRW+#3SK64BO
M.+^UQ/H_A#" /NNDHQ'/,JF^))NCR[3Y[D=D-1C*>0\<U=$X3F>@F)=Y:+=A
MK4UC\2OS?DI#UR+6;VAT'B-$IY0*EF7ESP5/F%$3H""BD1F&3(] >QDN]O5
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M^%@6[$K=)Z[J;&3%;W/L[PBCXBZC4 P)"*7E![;U&YL&@68TA_FH<2*=!94
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MQ8_X6<H/#,@>X6<I#[8P54L?PD^6_AM02P,$%     @ >##55 SY%W=6 P
M? \  !$   !I;VYS+3(P,C(P-C(Q+GAS9+5776_;(!1]G[3_P/Q.;"=MU41-
MJT[]4*5NG;)-VMM$,$[0;/  -\F_'^!@.\Y'8Z=37C#<<^ZYE\N%7-TLTP2\
M$B$I9V,O[ 4>( SSB++9V,LE1!)3ZMU<?_QP]0G"1\*(0(I$8+H"]W>/MY.8
M)MI4@F^3%STDX+(7F!_X+#B*!(UF!$(#7LJ1Q'.2(J"0F!'U%:5$9@B3L3=7
M*AOYOA9 939'(D4]S%._'_3[P44_U((2DA*F'KA([TB,\D2-O;\Y2FA,2>0!
M'0&3HZ4LF1:+16\QZ'$QTR1!Z/_Z\OS=^G:VVI4\PF]AK./[LT&]G(K$D0]\
MLSQ%DI0ZMNS74L+A<.C;U=)4$]$#U)1)A1@F=?M(E8"Z\;E?+#I3O7-JE9$J
MRAC)J35V*R;.$ 8A')212J'VH<JE';"(T$U-DN#>C+_Z>L&:EX9*-/@W8M;+
MOEDVF,"XT$A=.@"8XD&,<864WBP[M9[,,LIBOI[1<R:[([<C$Q(#F^^181U[
MDJ998I)IY^:"Q&//5 )T._X[$Z2GI3H3P1-R8'O,LJ\A4M>F5?9<.7842. M
MEJUZT"0\(T)1G=ZJG/QW"RM!T[9A:0A)_F\\AN>'C@"8P<_)T]X#:07=<9R;
M)G#+HGNFJ%H]Z8W7%B;O'J#1V#MH4?IVWB,24T9M/06Z1P0!@, QU(>(1:"@
M S6^*[])TN3/)8E>V+4=-VMDC5Z;'$)BE. \Z0"LE.W'K6?=/KASY3<.5C&Q
M>?S,X=-EQX4";*N1UUO-#*%LHV44E\ SQY:LP$C7.'8B?9(HZ69@Q=5;RLA5
MU4$]>WK2025-<S.POKMYQ3QG2JS:>*Y#W,<I"G(A],7>3D(=4WZ=(((L\;R-
M@-+>CDYPS!#%LHWG"E ,3_ M*6[CV9F;03NOS58^+#HG(S/S8MOMO@E+A-A
M0<,#PSX,+T[7H5IK4%W\;Z939:)5^IV]'9VV ?47W#&!6XCY@@YGPA^8\%NT
MNR;EF2_,_7VD &MMW)[!X!*&0;NL;[U&C_3J ,;Q^=$N#[]I3[AI+%F7JV:[
M]-</)JT5*TB668(84ERL'O3W\<>ASG)?D70Y'?4G?8=\.521*_.WH$.:WOA;
MT57)^VS;KK\A>R6]A;3?LA)B'U,%V?4_4$L#!!0    ( '@PU53SA"@%@0@
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MZJ;YH&\Q#4EP'@?M#USMRM7@[U./=H"*WEGS";0_:F"H$6^Z8D=2OWB3XCC
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M=(CU)J @P)FWIW+4\E<>%-/P6X!%Y!.:<13_35:5#:$ZH(UU PB<^[JTCE&
MX4?I '*'4#ZS1@PC"_,VD_HSH6:"QVY-Z U\ZB,5@Y#[=?+@5#Q9TM3>KZLR
M%^4HF^&QV9!" Z/ET8I5R V[/QCA'*>7-$G6:=%9R@QJ:S%%<2HP\$AV2::!
MZ0H7BF[(G;@G&I.0<)(NOHK71D90;'!=#2AJ8P/ 8[DQC0:*;>,5OY#[;!.&
MI2RQV GDISOD82+V,)^7;M?-P*)0=4!XO#NGU<!_G1^E \C=-B/^<9:M,7-6
M0R7<K@D+'+PRFE(\3A\6;THED#MR]W3*D#RO__22S&AL.5E5@R@*947 H[\Y
MD0;&K0[4&1SXW;?K!+.%B/Z6T0U?"NVN4&ION=0BM3UX!1(>^>Z).>W"*QPI
M,4!NO*FS9#<D$[N5OS!B-^**^<+?@#+.X)50\ 3@EI#C.;R2$T4\Y#Z<'OSN
M*&$S]1:<E7P-!YW^ZJ2.$H#F1DD <@MN=_.Z% DP%(_%J\KV"[8_ BHPVLV_
MA(%'NTLR3C?\D@M%-^1^W1,.UTP$WPMF4YFKN=&O,*MM?LD,C]^&%)JV^*71
MBE7(_3KM)=2@U&HKBF'8X)%9%WP#D\9012/H/EPAONMMN$3I EM.QM=!C$6J
M0^!QZY"*XV+5/2BF3^W(7?BE4MV)"_*?SW<6^4W^L_:G_P!02P$"% ,4
M" !X,-54O%5.=)@1  !=9   $P              @ $     8G)H8S$P,#,X
M.30S7SAK+FAT;5!+ 0(4 Q0    ( '@PU50F(J1$ Q,  +M4   7
M      "  <D1  !B<FAC,3 P,S@Y-#-?97@Y.2TQ+FAT;5!+ 0(4 Q0    (
M '@PU50,^1=W5@,  'P/   1              "  0$E  !I;VYS+3(P,C(P
M-C(Q+GAS9%!+ 0(4 Q0    ( '@PU53SA"@%@0@  ')8   5
M  "  88H  !I;VYS+3(P,C(P-C(Q7VQA8BYX;6Q02P$"% ,4    " !X,-54
M3%YPLN@%  #U/@  %0              @ $Z,0  :6]N<RTR,#(R,#8R,5]P
<<F4N>&UL4$L%!@     %  4 2P$  %4W      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
